GlassScriptPhysician profile
Brian A Anderson
NPI 1417058496
$5,941.48
in general payments reported to CMS, 2019-2025
30 companies · $904 in 2025
The $904 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $629 · 2020: $657 · 2021: $947 · 2022: $879 · 2023: $1,008 · 2024: $917 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,780 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,780.17 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $894.73 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $775.93 | 2019-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $531.07 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $414.27 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $352.15 | 2019-2024 | Trintellix |
| Allergan, INC. | $301.24 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $283.05 | 2022-2024 | Quviviq |
| Sunovion Pharmaceuticals INC. | $279.26 | 2019-2022 | |
| Bausch Health US, LLC | $270.76 | 2019-2022 | |
| Corium, LLC | $269.36 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $212.84 | 2019-2025 | Spravato |
| Eisai INC. | $201.66 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $182.81 | 2020-2024 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $177.09 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $170.82 | 2022-2025 | Qelbree, Qelbree |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $101.39 | 2024 | Xelstrym |
| Vertical Pharmaceuticals, LLC | $97.86 | 2024-2025 | Relexxii |
| Tris Pharma INC | $69.98 | 2022-2023 | Dyanavel Xr |
| Alfasigma USA, INC. | $58.56 | 2020-2022 | |
| Axsome Therapeutics, INC. | $42.74 | 2022-2023 | Auvelity |
| Alkermes, INC. | $31.91 | 2021-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $29.60 | 2019 | |
| Adlon Therapeutics L.P. | $29.42 | 2020 | |
| Avanir Pharmaceuticals, INC. | $29.13 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $29.08 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $28.70 | 2019-2021 | |
| Almatica Pharma LLC | $27.38 | 2021-2022 | |
| Neos Therapeutics, LP | $24.50 | 2019-2020 | |
| Shire North American Group INC | $12.12 | 2019 | |
| Jazz Pharmaceuticals INC. | $12.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.